NMPA accepts clinical trial application for monkeypox vaccine
chinadaily.com.cn |
Updated: 2023-07-14 19:44
Share
Share - WeChat
The National Medical Products Administration (NMPA) has, on Thursday, officially accepted the clinical trial application for the replication-deficient monkeypox vaccine developed by China National Pharmaceutical Group Corporation (Sinopharm) Beijing Institute of Biological Products.
- China implements new rules on the criminal liability of minor offenders
- China issues rules to strengthen overseas travel, exit-entry management
- Orange alert issued for geological disaster risks in three provinces
- Chongqing honors community worker killed during landslide evacuation
- China issues highest alert for flash flood risks amid heavy rain forecast
- Five government departments target malpractice in the matchmaking sector
